Intraocular Drug Delivery That Lasts | Spyglass Pharma

top of page

About Us
Our Technology
Pipeline
For Patients
More

Use tab to navigate through the menu items.

Our apologies. This site is under maintenance and will be back online shortly.

SpyGlass Pharma™ Completes Enrollment in Phase I/II Study of its Promising Long-Term Drug Delivery Platform for Glaucoma and Ocular Hypertension

ALISO VIEJO, Calif., November 19, 2024 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, today announced completion of enrollment in its Phase I/II, randomized, multi-center, controlled clinical trial (NCT06120842) evaluating SpyGlass’ Drug Delivery Platform in patients with glaucoma or ocular hypertension. The SpyGlass platform is designed to deliver multiple years of bimatoprost to lower intraocular pressure (IOP) and is implanted during routine cataract surgery. (View full press release)

Tel: 949-284-6904

27061 Aliso Creek Rd, Suite 100
Aliso Viejo, CA 92656

SUBSCRIBE

Sign up to receive SpyGlass Pharma™ news and updates.

Email

Thanks for submitting!

© 2024 SpyGlass Pharma™. All Rights Reserved.

Follow us on LinkedIn

bottom of page